小细胞肺癌NCCN指南2025第3版

根据ADRIATIC研究数据更新了度伐利尤单抗在局限期SCLC巩固治疗的地位（1类）

Durvalumab Consolidation Therapy

The ADRIATIC trial included patients with stage I–III limited-stage SCLC, PS 0–1 and no disease progression on chemoradiation. The median OS was 55.9 months in those patients receiving consolidation therapy (n = 264) compared to 33.4 months (P = 0.01) in patients receiving placebo (n = 266).118 The study revealed a statistically significant and clinically meaningful OS and PFS (16.6 months vs. 9.2 months, P = 0.02) improvement in patients receiving consolidation durvalumab compared to placebo. Based on this data, the Panel recommends durvalumab consolidation therapy in those patients with limited stage who did not experience disease progression after systemic therapy + concurrent RT (category 1). Durvalumab may be continued until disease progression or intolerable toxicity, or for a maximum of 24 months. Additionally, the Panel recommends if PCI is being considered in this setting it should be given prior to consolidation durvalumab.

ADRIATIC试验包括PS 0-1且化放疗后无疾病进展的Ⅰ-Ⅲ期局限期SCLC患者。接受巩固治疗的患 者（264例）的中位OS为55.9个月，而接受安慰剂治疗的患者（266例）为33.4个月（P=0.01）。研究 显示，与安慰剂相比，接受度伐利尤单抗巩固治疗的患者的OS和PFS（16.6个月对9.2个 月，P=0.02）有显著的统计学意义和临床意义。基于这些数据，专家组建议那些经全身治疗+同步放疗 后疾病未进展的局限期患者接受度伐利尤单抗巩固治疗（1类）。